Skip to main content

Table 1 Baseline characteristics of the participants in three groups

From: Evaluation of the additive effect of interferon α 2b with monthly intravitreal injection of bevacizumab in refractory diabetic macular edema

Variables

Group 1 (IVB + IFN Drop)

N = 14 (23 eyes)

Group 2 (IVB + IFN Injection)

N = 10 (16 eyes)

Group 3 (IVB)

N = 11(20 eyes)

p-value

Age (years)

63 ± 8

62 ± 9

59 ± 6

0.352

Sex number (%)

 Female

13 (56%)

9 (57%)

3 (15%)

0.007

 Male

10 (34%)

7 (43%)

17 (85%)

Spherical Equivalence (diopter) mean ± SD

0.64 ± 1.15

0.89 ± 1.85

0.84 ± 1.5

0.866

Lens Status number (%)

 Pseudophakic

10 (43%)

7 (43%)

6(30%)

0.597

 Phakic

13(56%)

9 (57%)

14(70%)

 HbA1C (%) mean ± SD

7.73 ± 1.01

8.04 ± 0.64

7.69 ± 0.72

0.370

 IOP (mmHg) mean ± SD

17 ± 4.3

16 ± 4

17 ± 2.5

0.592

 CMT (microns) mean ± SD

566 ± 202

560 ± 238

543 ± 179

0.923

 CDVA (logMAR) mean ± SD

0.91 ± 0.56

0.71 ± 0.43

0.76 ± 0.49

0.529

  1. Bold values denote statistical significance at the p-value < 0.05 level
  2. IVB, intravitreal bevacizumab; HbA1C, glycated hemoglobin; IOP, intraocular pressure; CMT, central macular thickness; CDVA corrected distal visual acuity